Electronic microarray technique for detection of nine base substitutions including single-nucleotide polymorphisms in the human OGG1 gene.

Oncol 2000;5:3–10. 3. Wright GL Jr. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2002;2:549–63. 4. Adam B-L, Yinsheng Q, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609–14. 5. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48:1835–43. 6. Petricoin EF, Ardekani A, Hitt B, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572–7. 7. Li J, Zhang Z, Rosenweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296–304. 8. Vlahou A, Schorge J, Gregory BW, Coleman R. Diagnosis of ovarian cancer using decision tree classification of mass spectral data J. Biomed Biotechnol 2003;5:308–14. 9. Vlahou A, Laronga C, Wilson L, Gregory B, McGaugher D, Perry RR, et al. A novel approach towards development of a rapid blood test for breast cancer. Clin Breast Cancer 2003;4:203–9. 10. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis; identification of key issues affecting potential clinical utility. Cancer Res 2003;63:6971–83. 11. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, et al. Development of a novel proteomic approach for the detection of bladder cancer. Am J Pathol 2001;158:1491–502. 12. Davuluri RV, Suzuki Y, Sugano S, Zhang MQ. CART classification of human 5 UTR sequences. Genome Res 2000;10:1807–16. 13. Giannopoulos A, Manousakas T, Gounari A, Constantinides C, ChoremiPapadopoulou H, Dimopoulos C. Comparative evaluation of the diagnostic performance of the BTAstat, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 2001;166:488–9. 14. Lotan Y, Boehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61:109–18. 15. Giannopoulos A, Manousakas T, Mitropoulos D, Botsoli-Stergiou E, Constantinides C, Giannopoulou M, et al. Comparative evaluation of the BTAstat test, NMP22 and voided urine cytology in the detection of primary and recurrent bladder tumors. Urology 2002;55:871–5.